ArticleRSC advances2021
Concurrent occurrence of electrochemical dissolution/deposition of cobalt-calcium phosphate composite.
Article in RSC advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amorphous cobalt-calcium phosphate composite (CCPC) films are electrochemically prepared on various electrodes by utilizing the solid phase of hydroxyapatite as a phosphate source. The CCPC film formation is surface process in which the dissolution of hydroxyapatite and the deposition of CCPC film concurrently occur on the electrode surface without the mass transfer of phosphate ions into the bulk solution. Elemental, crystallographic, and morphological analyses (EDX, ICP-AES, XPS, and XRD) indicate that the CCPC is composed of amorphous cobalt oxide with calcium and phosphate. The film exhibits durable oxygen evolution reaction (OER) catalytic properties under neutral and basic aqueous condition. Compared to using solution phase of phosphate source, our preparation method utilizing solid hydroxyapatite has advantage of preventing unnecessary chemical reaction between phosphate and other chemical species in bulk solution.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.